VALIDATED EXECUTIVE ENGAGEMENTS
POOL + OUTREACH
752
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
152
Interactions with Platform & by Email
PARTICIPANTS
32
Unique # Participated
VALIDATIONS
14
Responses Validated*
* Login to view program details and full enterprise executive list.
DATE
SEP 2020
TABLES
159
PAGES
235
EDITION
6
PRICE
USD $4950
Tapping into New Geographical Markets is a Great Way to Grow!
What's Your Addressable Opportunity in the PEGylated Proteins Market?
Amid the COVID-19 crisis, the global market for PEGylated Proteins estimated at US$903.9 Million in the year 2020, is projected to reach a revised size of US$1.7 Billion by 2027, growing at a CAGR of 9.1% over the period 2020-2027.Consumables, one of the segments analyzed in the report, is projected to grow at a 8.5% CAGR to reach US$1.1 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Services segment is readjusted to a revised 10.4% CAGR for the next 7-year period. This segment currently accounts for a 29.9% share of the global PEGylated Proteins market.
The PEGylated Proteins market in the U.S. is estimated at US$267.7 Million in the year 2020. The country currently accounts for a 29.61% share in the global market. China, the world second largest economy, is forecast to reach an estimated market size of US$288.9 Million in the year 2027 trailing a CAGR of 8.5% through 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.5% and 7.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.4% CAGR while Rest of European market (as defined in the study) will reach US$288.9 Million by the year 2027.We bring years of research experience to this 6th edition of our report. The 235-page report presents concise insights into how the pandemic has impacted production and the buy side for 2020 and 2021. A short-term phased recovery by key geography is also addressed.
Biomatrik; Celares GmbH; Creative PEGWorks; Iris Biotech GmbH; Jenkem Technology Co., Ltd.; Laysan Bio, Inc.; MilliporeSigma; Nof American Corporation; Quanta Biodesign, Ltd.; Thermo Fisher Scientific, Inc.
» End-Use (Pharmaceutical & Biotechnology Companies, Contract Research Organizations, Academic Research Institutes) » Product (Consumables, Services) » Protein Type (Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII, Other Protein Types)
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
INSIDER ACCESS PRIVILEGES
Users of our portal have insider access to our data stacks based on project relevance and engagement status. Tiered access is offered to data stacks, managed based on user status - Opt-in, Active Panelist, Inactive Panelist, Active Client or Inactive Client.
KEY DIFFERENTIATORS
We are firmly committed to build upon perspectives from global executive insights. These engagements enrich our projects. Our primary research programs are fully validated and accessible by clients. (Its a common industry-wide* practice that no validated primary research is done! For the most part, remote resident analysts curate and write reports drawing on search engine research and data modeling.
* A review of 262 off-the-shelf market report publishers worldwide.
WHAT SETS US APART
Client companies can access multiple features on our MarketGlass™ platform.
Clients have full-stack insider access to our ongoing primary research program. We have a very successful incentive driven primary research program that benefits participating executives regardless of their purchase decision. Our platform presents a unique opportunity to collaborate with peers and review competitors’ inputs and response clusters.
Detailed engagement stats are presented for every company and executive contacted. This is made available for our client reviews. (no other publisher offers this!)
A full-stack access to clients of all primary and secondary source content. This can often run into thousands of pages.
Where relevent and possible we present competitive brands.
Peer-to-peer online interactive collaborations. Allows for team curated bespoke analytics.
Customers can update and build bespoke versions of our analytics. Bespoke updates are fulfilled within a two-day turnaround.
Discretely bounce off queries to participant pool of executives. Our embedded AI selectively pings participants geographically and by domain acumen.
We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.
Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.
All updates are offered for one year from date of your purchase without charge. Clients can opt for annual auto renewal and stay current without interruption.
05
| I. INTRODUCTION, METHODOLOGY & REPORT SCOPE |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Impact of Covid-19 and a Looming Global Recession |
| Global Competitor Market Shares |
| PEGylated Proteins Competitor Market Share Scenario Worldwide (in %): 2018E |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for PEGylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 |
| World Historic Review for PEGylated Proteins by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| World 15-Year Perspective for PEGylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2012, 2018 & 2027 |
| World Current & Future Analysis for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 |
| World Historic Review for Consumables by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| World 15-Year Perspective for Consumables by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 |
| World Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 |
| World Historic Review for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| World 15-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 |
| World Current & Future Analysis for Colony Stimulating Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 |
| World Historic Review for Colony Stimulating Factors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| World 15-Year Perspective for Colony Stimulating Factors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 |
| World Current & Future Analysis for Interferons by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 |
| World Historic Review for Interferons by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| World 15-Year Perspective for Interferons by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 |
| World Current & Future Analysis for Erythropoietin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 |
| World Historic Review for Erythropoietin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| World 15-Year Perspective for Erythropoietin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 |
| World Current & Future Analysis for mAbs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 |
| World Historic Review for mAbs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| World 15-Year Perspective for mAbs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 |
| World Current & Future Analysis for Recombinant Factor VIII by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 |
| World Historic Review for Recombinant Factor VIII by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| World 15-Year Perspective for Recombinant Factor VIII by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 |
| World Current & Future Analysis for Other Protein Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 |
| World Historic Review for Other Protein Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| World 15-Year Perspective for Other Protein Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 |
| World Current & Future Analysis for Pharmaceutical & Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 |
| World Historic Review for Pharmaceutical & Biotechnology Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| World 15-Year Perspective for Pharmaceutical & Biotechnology Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 |
| World Current & Future Analysis for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 |
| World Historic Review for Contract Research Organizations by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| World 15-Year Perspective for Contract Research Organizations by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 |
| World Current & Future Analysis for Academic Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 |
| World Historic Review for Academic Research Institutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| World 15-Year Perspective for Academic Research Institutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2012, 2018 & 2027 |
| III. MARKET ANALYSIS |
| GEOGRAPHIC MARKET ANALYSIS |
| United States |
| Market Facts & Figures |
| US PEGylated Proteins Market Share (in %) by Company: 2018 & 2027 |
| USA Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| USA Historic Review for PEGylated Proteins by Product - Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| USA 15-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2012, 2018 & 2027 |
| USA Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| USA Historic Review for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| USA 15-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2012, 2018 & 2027 |
| USA Current & Future Analysis for PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| USA Historic Review for PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| USA 15-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes for the Years 2012, 2018 & 2027 |
| Canada |
| Canada Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| Canada Historic Review for PEGylated Proteins by Product - Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Canada 15-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2012, 2018 & 2027 |
| Canada Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| Canada Historic Review for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Canada 15-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2012, 2018 & 2027 |
| Canada Current & Future Analysis for PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| Canada Historic Review for PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Canada 15-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes for the Years 2012, 2018 & 2027 |
| Japan |
| Japan Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| Japan Historic Review for PEGylated Proteins by Product - Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Japan 15-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2012, 2018 & 2027 |
| Japan Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| Japan Historic Review for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Japan 15-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2012, 2018 & 2027 |
| Japan Current & Future Analysis for PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| Japan Historic Review for PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Japan 15-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes for the Years 2012, 2018 & 2027 |
| China |
| China Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| China Historic Review for PEGylated Proteins by Product - Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| China 15-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2012, 2018 & 2027 |
| China Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| China Historic Review for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| China 15-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2012, 2018 & 2027 |
| China Current & Future Analysis for PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| China Historic Review for PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| China 15-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes for the Years 2012, 2018 & 2027 |
| Europe |
| Market Facts & Figures |
| European PEGylated Proteins Market: Competitor Market Share Scenario (in %) for 2018 & 2027 |
| Europe Current & Future Analysis for PEGylated Proteins by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2018 through 2027 |
| Europe Historic Review for PEGylated Proteins by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Europe 15-Year Perspective for PEGylated Proteins by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2012, 2018 & 2027 |
| Europe Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| Europe Historic Review for PEGylated Proteins by Product - Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Europe 15-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2012, 2018 & 2027 |
| Europe Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| Europe Historic Review for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Europe 15-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2012, 2018 & 2027 |
| Europe Current & Future Analysis for PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| Europe Historic Review for PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Europe 15-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes for the Years 2012, 2018 & 2027 |
| France |
| France Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| France Historic Review for PEGylated Proteins by Product - Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| France 15-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2012, 2018 & 2027 |
| France Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| France Historic Review for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| France 15-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2012, 2018 & 2027 |
| France Current & Future Analysis for PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| France Historic Review for PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| France 15-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes for the Years 2012, 2018 & 2027 |
| Germany |
| Germany Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| Germany Historic Review for PEGylated Proteins by Product - Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Germany 15-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2012, 2018 & 2027 |
| Germany Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| Germany Historic Review for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Germany 15-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2012, 2018 & 2027 |
| Germany Current & Future Analysis for PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| Germany Historic Review for PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Germany 15-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes for the Years 2012, 2018 & 2027 |
| Italy |
| Italy Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| Italy Historic Review for PEGylated Proteins by Product - Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Italy 15-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2012, 2018 & 2027 |
| Italy Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| Italy Historic Review for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Italy 15-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2012, 2018 & 2027 |
| Italy Current & Future Analysis for PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| Italy Historic Review for PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Italy 15-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes for the Years 2012, 2018 & 2027 |
| United Kingdom |
| UK Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| UK Historic Review for PEGylated Proteins by Product - Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| UK 15-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2012, 2018 & 2027 |
| UK Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| UK Historic Review for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| UK 15-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2012, 2018 & 2027 |
| UK Current & Future Analysis for PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| UK Historic Review for PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| UK 15-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes for the Years 2012, 2018 & 2027 |
| Rest of Europe |
| Rest of Europe Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| Rest of Europe Historic Review for PEGylated Proteins by Product - Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Rest of Europe 15-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2012, 2018 & 2027 |
| Rest of Europe Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| Rest of Europe Historic Review for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Rest of Europe 15-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2012, 2018 & 2027 |
| Rest of Europe Current & Future Analysis for PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| Rest of Europe Historic Review for PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Rest of Europe 15-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes for the Years 2012, 2018 & 2027 |
| Asia-Pacific |
| Asia-Pacific Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| Asia-Pacific Historic Review for PEGylated Proteins by Product - Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Asia-Pacific 15-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2012, 2018 & 2027 |
| Asia-Pacific Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| Asia-Pacific Historic Review for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Asia-Pacific 15-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2012, 2018 & 2027 |
| Asia-Pacific Current & Future Analysis for PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| Asia-Pacific Historic Review for PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Asia-Pacific 15-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes for the Years 2012, 2018 & 2027 |
| Rest of World |
| Rest of World Current & Future Analysis for PEGylated Proteins by Product - Consumables and Services - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| Rest of World Historic Review for PEGylated Proteins by Product - Consumables and Services Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Rest of World 15-Year Perspective for PEGylated Proteins by Product - Percentage Breakdown of Value Sales for Consumables and Services for the Years 2012, 2018 & 2027 |
| Rest of World Current & Future Analysis for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| Rest of World Historic Review for PEGylated Proteins by Protein Type - Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Rest of World 15-Year Perspective for PEGylated Proteins by Protein Type - Percentage Breakdown of Value Sales for Colony Stimulating Factors, Interferons, Erythropoietin, mAbs, Recombinant Factor VIII and Other Protein Types for the Years 2012, 2018 & 2027 |
| Rest of World Current & Future Analysis for PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes - Independent Analysis of Annual Sales in US$ Thousand for the Years 2018 through 2027 |
| Rest of World Historic Review for PEGylated Proteins by End-Use - Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2012 through 2017 |
| Rest of World 15-Year Perspective for PEGylated Proteins by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Biotechnology Companies, Contract Research Organizations and Academic Research Institutes for the Years 2012, 2018 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled : 46 Click here to request a full table of contents and more details on this project. |
INSIDER ACCESS TO
METHODOLOGY
QUESTIONNAIRE
INFLUENCER NETWORK
Registration is required to access our data stacks.
RESEARCH PANEL
Panelists are carefully chosen based on their domain expertise and market influence.
Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.
Our panelists give 30-minutes a month or a one-time 30-minute participation based on their time and willingness.
- Complimentary previews of full stack research data for participated
- Insider access to research programs including engagements and stats from other panelists
- Unlimited research credits of $1000 per participated project
- Competitive Intelligence Alerts including engagements from other panelists and validated participants worldwide relevant to your company
- Interact with other panelists via our MarketGlassTM Data Exchange Platform*
- BlogX - Panelists can use our blogging platform publish their viewpoints on news relevant to their domain expertise. Platform enables panelists to share their viewpoints on current news and events related to their areas domain expertise with timely and insightful blogs*
* Complete details will be shared with panelists upon formal acceptance.
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com